Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Edelman

Showing results (661-670 of 674) with videos related to

Pageof 68
Sort By:
The American Journal of Cardiology|November 29, 2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr, Peter R Kowey, Richard B Devereux, et al.
JAMA|November 18, 2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular eventsPeter M Okin, Richard B Devereux, Sverker Jern, et al.
Allergy|October 5, 2023
EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assuranceM Pascal, S M Edelman, A Nopp, et al.
Pharmacogenetics and Genomics|January 13, 2010
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE studyBørge G Nordestgaard, Kimmo Kontula, Marianne Benn, et al.
Cell|June 26, 2012
Gut immune maturation depends on colonization with a host-specific microbiotaHachung Chung, Sünje J Pamp, Jonathan A Hill, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare DiseasesAdam Wanner, Stephen C Groft, J Russell Teagarden, et al.
Blood Pressure|December 17, 2009
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension studySverre E Kjeldsen, Richard B Devereux, Darcy A Hille, et al.
Journal of the American College of Cardiology|September 6, 2005
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) studyEigil Fossum, Andreas Moan, Sverre E Kjeldsen, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophyFrej Fyhrquist, Björn Dahlöf, Richard B Devereux, et al.
Pageof 68

Showing results (661-670 of 674) with videos related to

Sort By:
Pageof 68
The American Journal of Cardiology|November 29, 2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr, Peter R Kowey, Richard B Devereux, et al.
JAMA|November 18, 2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular eventsPeter M Okin, Richard B Devereux, Sverker Jern, et al.
Allergy|October 5, 2023
EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assuranceM Pascal, S M Edelman, A Nopp, et al.
Pharmacogenetics and Genomics|January 13, 2010
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE studyBørge G Nordestgaard, Kimmo Kontula, Marianne Benn, et al.
Cell|June 26, 2012
Gut immune maturation depends on colonization with a host-specific microbiotaHachung Chung, Sünje J Pamp, Jonathan A Hill, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare DiseasesAdam Wanner, Stephen C Groft, J Russell Teagarden, et al.
Blood Pressure|December 17, 2009
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension studySverre E Kjeldsen, Richard B Devereux, Darcy A Hille, et al.
Journal of the American College of Cardiology|September 6, 2005
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) studyEigil Fossum, Andreas Moan, Sverre E Kjeldsen, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophyFrej Fyhrquist, Björn Dahlöf, Richard B Devereux, et al.
Pageof 68